Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

Part of paid clinical trials in Anchorage, Alaska.

Sponsor
AstraZeneca
Study ID
NCT07816666
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Platinum-sensitive Relapsed Epithelial Ovarian Cancer
  • Platinum-sensitive Relapsed Fallopian Tube Cancer
  • Platinum-sensitive Relapsed Primary Peritoneal Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Torvutatug samrotecan — DRUG
    FRa targeting antibody drug conjugate Topoisomerase I inhibitor
  • Bevacizumab — DRUG
    Monoclonal antibody inhibitor of Vascular Endothelial Growth Factor

Study Details

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)

Key Dates

First listed
Sep 14, 2026
Start date
Sep 29, 2026
Status verified
Sep 2026
Primary completion
Sep 26, 2028
Completion
Oct 27, 2031

Study Design

Enrollment
600 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Torvutatug samrotecan monotherapy or in combination with bevacizumab
    Torvutatug samrotecan monotherapy intravenous (IV) or Torvutatug samrotecan IV with bevacizumab IV.
  • Active Comparator: Observation or bevacizumab
    Observation or bevacizumab IV.

Primary Outcome Measure

Progression-Free Survival (PFS) [ Time Frame: Up to approximately 5 years ]

Central Contacts

Locations (16)

FacilityCityStateZIPSite coordinators
Research SiteAnchorageAlaska99508-
Research SiteColumbiaMaryland21044-
Research SiteDetroitMichigan48201-
Research SiteAlbanyNew York12206-
Research SiteBay ShoreNew York11706-
Research SiteGreenlawnNew York11740-
Research SiteNew Hyde ParkNew York11042-
Research SiteNew YorkNew York10029-
Research SiteRego ParkNew York11374-
Research SiteClevelandOhio44111-
Research SiteClevelandOhio44195-
Research SiteColumbusOhio43210-
Research SiteMayfield HeightsOhio44124-
Research SitePhiladelphiaPennsylvania19107-
Research SiteWillow GrovePennsylvania19090-
Research SiteMorgantownWest Virginia26506-